Category: Oncotarget

Oncotarget News

Oncotarget | Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

November 29, 2022

MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.”BUFFALO, NY- November 29, 2022 – A new review was published in Oncotarget's Volume 13... read more

Oncotarget

Oncotarget | Treasures From Trash in Cancer Research

November 23, 2022

Most of these supposed useless data are often treated as trash and remain unexplored. However, in some cases, treasures hidden in these data are discarded [2, 4].”BUFFALO, NY- November... read more

Oncotarget

Oncotarget | Association of Fall Rate and Functional Status by APOE Genotype in Cancer Survivors After Exercise Intervention

November 21, 2022

This is the first examination of the relationship among exercise, apoE genotype, and side effects and symptoms of cancer in a subset of older female cancer survivors participating in a... read more

Oncotarget

Oncotarget | Mutation Analysis Performed on Tumor Biopsies From Patients With Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas

November 17, 2022

Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS [disease free survival] following treatment with... read more

Oncotarget

Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway

November 10, 2022

In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.”BUFFALO, NY-... read more

Oncotarget

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].”BUFFALO, NY- November 9,... read more

Oncotarget

Oncotarget | Predictive Molecular Biomarkers for Determining Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer

November 8, 2022

To our knowledge, our study is the first to use combined differential mRNA and miRNA expression in MIBC to identify a NAC response signature.”BUFFALO, NY- November 8, 2022 – A... read more

Oncotarget

Oncotarget | Serine Protease Matriptase Inhibits Migration and Proliferation in Multiple Myeloma Cells

November 7, 2022

We demonstrate that matriptase overexpression in vitro was associated with reduced myeloma cell proliferation and that matriptase significantly inhibited myeloma cell migration.”BUFFALO, NY- November 7, 2022 – A new research... read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.”BUFFALO, NY- November 3,... read more

Oncotarget

Oncotarget is Again on MEDLINE

October 27, 2022

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed.The United... read more